Author Index to Volume 46

(ASHG) = American Society of Human Genetics report; (BR) = Book Review; (E) = Editorial; (HGES) = Human Genetics Education section; (L) = Letter to the Editor; (O) = Opinion; (R) = Review

Abidi, F., 95
Abraham, N. G., 107
Ad Hoc Committee on Individual Identification by DNA Analysis, 631 (ASHG)
Aklog, L., 559
Albers, J. J., 822
Allitto, B. A., 762
Amos, C., 266
Anderson, I. J., 896
Anderson, L., 624
Angert E., 26
Anvret, M., 1073
Archidiacono, N., 738, 784
Ardinger, H. H., 486
Arduino, J. M., 581
Arias, T. D., 63
Arnason, A., 293
Arpagaus, M., 934
Arveiler, B., 906
Aston, C. E., 879
Aubourg, P., 459
Auburger, G., 1163
Auwerx, J. H., 470
Awa, A. A., 1053
Azofeifa, J., 63

Babirak, S. P., 470
Babu, V. R., 1101
Bachinski, L. L., 492, 1073
Bachman, H., 156
Bäckman, B., 120
Badner, J. A., 568
Bailly, J., 1082
Baker, E., 107
Baker, R. T., 308
Baldini, A., 784
Ballinger, S. W., 613
Barker, P. E., 182 (L)
Barrantes, R., 63
Barrow, M., 1112
Bartels, C. F., 934
Bartolucci, G., 738
Barton, N. J., 925, 1112
Basta, M., 377
Bates, G. P., 762
Baumiller, R. C., 215 (HGES-BR), 1234 (HGES-BR)
Baute, L. H., 1163
Bawden, M. J., 107
Baxendale, S., 762
Beaudet, A. L., 393 (ASHG)
Beighton, P., 293
Berciano, J., 92
Besa, E., 26
Bethlenfalvay, N. C., 1112
Beutler, E., 902
Biesecker, B. B., 1223 (HGES)
Bigley, R. H., 652
Bishop, D. T., 254
Blake, W., 1223 (HGES)
Blanc, M., 383
Blass, J. P., 874
Blitzer, M. G., 1001 (L)
Bloch, M., 1 (O)
Blouin, J. L., 518
Blumberg, B., 591
Board, P. G., 308
Bodurtha, J., 190 (HGES)
Boehnke, M., 581
Borecki, I. B., 37
Børreson, A.-L., 293
Bottomley, S. S., 107
Bouchard, C., 37
Bowcock, A. M., 12, 795
Bowden, D. K., 144
Brandt, I. K., 843
Brantly, M. L., 810
Breguet, G., 502
Breslow, J. L., 1141
Bressman, S. B., 533
Brewster, M. A., 1001 (L)
Brin, M. F., 533
Brinkman, A. O., 1095
Brown, A., 329
Brown, C. J., 273
Brown, K. W., 1000 (L)
Brunner, H., 1073
Brunzell, J. D., 112, 470
Buckle, V. J., 1112, 1127
Budarf, M., 888
Buetow, K. H., 486
Buist, N. R. M., 1001 (L)
Burgio, R. G., 661
Burke, R. E., 533
Burns, J., 208 (HGES)
Burton, B. K., 1001 (L)
Bütler, R., 502
Bütler-Brunner, E., 502
Buxton, J., 1073
Byers, P. H., 591, 975, 1034

Cannizzaro, L. A., 26
Cannon-Albright, L. A., 912
Capote, R. F., 1163
Carey, J. C., 943
Carson, N. L., 624
Caskey, C. T., 393 (ASHG)
Castiglione, C. M., 624
Cavalli-Sforza, L. L., 649 (O)
Cetta, G., 661
Chakravarti, A., 568, 801
Chamberlain, S., 1163
Chang, C., 1095
Chang, H. J., 156
Chang, P. L., 395 (L), 729
Charmley, P., 789
Cheang, M. S., 280
Chen, L. Z., 107
Chery, M., 133
Chettouh, Z., 518
Chevenix-Trench, G., 635 (L)
Chi, Y.-T., 340
Childs, B., 848 (BR)
Chodirker, B. N., 280, 286
Chui, D. H. K., 1127
Ciampi, A., 434
Clark, R. D., 156
Claus, E. B., 533
Clegg, J. B., 144
Coerwinkel, M., 492
Cohen, J. E., 358
Cohen, M., 185 (BR)
Cohn, D. H., 591
Collinge, J., 1215 (L)
Colombo, J. P., 1001 (L)
Concannon, P., 789
Conover, B., 1223 (HGES)

Author Index to Volume 46

(ASHG) = American Society of Human Genetics report; (BR) = Book Review; (E) = Editorial; (HGES) = Human Genetics Education section; (L) = Letter to the Editor; (O) = Opinion; (R) = Review

Abidi, F., 95
Abraham, N. G., 107
Ad Hoc Committee on Individual Identification by DNA Analysis, 631 (ASHG)
Aklog, L., 559
Albers, J. J., 822
Allitto, B. A., 762
Amos, C., 266
Anderson, I. J., 896
Anderson, L., 624
Angert E., 26
Anvret, M., 1073
Archidiacono, N., 738, 784
Ardinger, H. H., 486
Arduino, J. M., 581
Arias, T. D., 63
Arnason, A., 293
Arpagaus, M., 934
Arveiler, B., 906
Aston, C. E., 879
Aubourg, P., 459
Auburger, G., 1163
Auwerx, J. H., 470
Awa, A. A., 1053
Azofeifa, J., 63

Babirak, S. P., 470
Babu, V. R., 1101
Bachinski, L. L., 492, 1073
Bachman, H., 156
Bäckman, B., 120
Badner, J. A., 568
Bailly, J., 1082
Baker, E., 107
Baker, R. T., 308
Baldini, A., 784
Ballinger, S. W., 613
Barker, P. E., 182 (L)
Barrantes, R., 63
Barrow, M., 1112
Bartels, C. F., 934
Bartolucci, G., 738
Barton, N. J., 925, 1112
Basta, M., 377
Bates, G. P., 762
Baumiller, R. C., 215 (HGES-BR), 1234 (HGES-BR)
Baute, L. H., 1163
Bawden, M. J., 107
Baxendale, S., 762
Beaudet, A. L., 393 (ASHG)
Beighton, P., 293
Berciano, J., 92
Besa, E., 26
Bethlenfalvay, N. C., 1112
Beutler, E., 902
Biesecker, B. B., 1223 (HGES)
Bigley, R. H., 652
Bishop, D. T., 254
Blake, W., 1223 (HGES)
Blanc, M., 383
Blass, J. P., 874
Blitzer, M. G., 1001 (L)
Bloch, M., 1 (O)
Blouin, J. L., 518
Blumberg, B., 591
Board, P. G., 308
Bodurtha, J., 190 (HGES)
Boehnke, M., 581
Borecki, I. B., 37
Børreson, A.-L., 293
Bottomley, S. S., 107
Bouchard, C., 37
Bowcock, A. M., 12, 795
Bowden, D. K., 144
Brandt, I. K., 843
Brantly, M. L., 810
Breguet, G., 502
Breslow, J. L., 1141
Bressman, S. B., 533
Brewster, M. A., 1001 (L)
Brin, M. F., 533
Brinkman, A. O., 1095
Brown, A., 329
Brown, C. J., 273
Brown, K. W., 1000 (L)
Brunner, H., 1073
Brunzell, J. D., 112, 470
Buckle, V. J., 1112, 1127
Budarf, M., 888
Buetow, K. H., 486
Buist, N. R. M., 1001 (L)
Burgio, R. G., 661
Burke, R. E., 533
Burns, J., 208 (HGES)
Burton, B. K., 1001 (L)
Bütler, R., 502
Bütler-Brunner, E., 502
Buxton, J., 1073
Byers, P. H., 591, 975, 1034

Cannizzaro, L. A., 26
Cannon-Albright, L. A., 912
Capote, R. F., 1163
Carey, J. C., 943
Carson, N. L., 624
Caskey, C. T., 393 (ASHG)
Castiglione, C. M., 624
Cavalli-Sforza, L. L., 649 (O)
Cetta, G., 661
Chakravarti, A., 568, 801
Chamberlain, S., 1163
Chang, C., 1095
Chang, H. J., 156
Chang, P. L., 395 (L), 729
Charmley, P., 789
Cheang, M. S., 280
Chen, L. Z., 107
Chery, M., 133
Chettouh, Z., 518
Chevenix-Trench, G., 635 (L)
Chi, Y.-T., 340
Childs, B., 848 (BR)
Chodirker, B. N., 280, 286
Chui, D. H. K., 1127
Ciampi, A., 434
Clark, R. D., 156
Claus, E. B., 533
Clegg, J. B., 144
Coerwinkel, M., 492
Cohen, J. E., 358
Cohen, M., 185 (BR)
Cohn, D. H., 591
Collinge, J., 1215 (L)
Colombo, J. P., 1001 (L)
Concannon, P., 789
Conover, B., 1223 (HGES)

Cook, E. J., 587
Cook, J. D., 672
Cooper, M., 1141
Cooper, T., 95
Cortada, J. M., 672
Cox, T. C., 107
Crabb, D. W., 843
Craik, C. S., 795
Crane, A. M., 539
Croce, C. M., 26
Crow, T. J., 1215 (L)
Crystal, R. G., 810
Cupples, L. A., 533
Curiel, D. T., 810

Dacou-Voutetakis, C., 988
Dahl, N., 120
Davidson, R. G., 729
Davies, J., 1073
Dazzo, C., 1194
Dean, P. N., 1218 (BR)
DeBauche, D. M., 530
DeBraekeleer, M., 126
Decklebaum, R. J., 1141
Deeb, S. S., 112, 470, 822
de Graaf, J., 1141
de Jong, P., 492
Delabar, J. M., 518
de la Chapelle, A., 53
del Cueto, M. E., 1163
deLeon, D., 533
Della Valle, G., 95
de Saint-Basile, G., 906
Devlin, R. H., 112
Devoto, M., 1004 (L)
Diaz, G. O., 1163
DiMauro, S., 418
Djurdjinovic, L., 1223 (HGES)
Dracopoli, N. C., 988
Drakopoulou, M., 988
Driesel, A. J., 133
Duff, C., 1082
d'Urso, M., 95, 720

Eisensmith, R. C., 18, 919
Elias, S., 847 (L)
Ellis, N., 950
Elsas, L. J., 1001 (L)
Emanuel, B. S., 888
Erickson, R. P., 637 (BR), 1013 (E)
Eto, R., 1041
Evans, J. E., 280, 286
Eyal, N., 527

Faber, J.-P., 1158
Fagan, K., 308
Fahn, S., 533
Falk, C. T., 1156
Falk, H., 1156
Falk, P. M., 486
Falk, R. E., 486
Fancello, G. S., 738
Farrall, M., 1163
Fell, R., 459, 720
Feltquate, D. M., 988
Fermanian, J., 518
Fibison, W. J., 888
Filippi, G., 738
Finan, J., 26
Firon, N., 527
Fischel-Ghodsian, N., 1127
Fischer, A., 906
Fisher, N. L., 208 (HGES)
Fletcher, J. C., 1200
Foy, C., 1017
Franco, B., 801
Frey, D., 293
Friedmann, T., 407 (O)
Fujii, J., 1082
Fujita, R., 133
Fujiwara, T. M., 434, 983
Fukumaki, Y., 602

Gan, Y.-Y., 613
Garcia, C., 801
Gardner, R. J. M., 486
Gardner-Medwin, D., 1127
Garver, K. L., 568
Gatti, R. A., 789
Gelbert, T., 902
Genel, M., 624
Germino, G. G., 925
Gershowitz, H., 63
Gilbert, F., 394 (L)
Gilgenkrantz, S., 133
Gitschier, J., 53
Gitzelmann, R., 18
Glinski, L. P., 486
Goate, A. M., 316
Goddard, A. D., 1024
Godfrey, M., 652, 661
Golbus, M. S., 847 (L)
Goldberg, R. B., 896
Goldgar, D. E., 912
Goldsmith, B. M., 1001 (L)
Goodfellow, P. J., 950
Goodfellow, P. N., 950
Graeser, C., 934
Gravel, R., 183 (L)
Green, P. P., 486
Greenberg, C. R., 280, 286
Greenberg, F., 888
Greene, R. E., 533
Greer, W., 395 (L)
Greger, V., 1187
Griscelli, C., 906
Grossman, L. I., 415 (E)
Grzeschik, K.-H., 492, 874
Guethlein, L. A., 192 (HGES)
Guidoux, S., 459
Guo, Z., 776
Gusella, J. F., 5, 323, 762
Guttenbach, M., 553
Güttler, F., 919

Haines, J. L., 323
Hake, L., 795
Hall, J. G., 857 (R), 1007 (BR)
Hall, J. M., 12
Hammond, J., 1001 (L)
Hanauer, A., 133
Harada, F., 1178
Harding, A. E., 92, 428
Hardy, J. A., 316
Harkness, E. M., 486
Harley, H., 1073
Harris, P., 925
Harris, P. C., 1112
Harris, R., 1017
Harris, R. A., 843
Hassold, T. J., 754
Haworth, J. C., 286
Hayasaka, K., 828
Hayden, M. R., 1, (O), 112, 1217 (BR)
Hebert, J. M., 12
Hecht, B. K., 400 (BR)
Hecht, F., 400 (BR)
Heiberg, A., 293
Heilig, R., 720
Henry, W. M., 729
Hertzberg, M. S., 138
Higgs, D. R., 925, 1112, 1127
Hill, A. V. S., 144
Hill, S. Y., 879

Hobbs, H. H., 963
Hodge, J. A., 613
Hoefsloot, L. H., 45
Hoeijmakers, J., 492
Hoffman, E. P., 672
Hokanson, J. E., 470
Hollister, D. W., 652, 661
Holmes, M. D., 810
Holt, I. J., 428
Hommes, F. A., 1001 (L)
Hoogeveen-Westerveld, M., 45
Hook, E. B., 1219 (BR)
Hori, H., 661
Horai, S., 828
Horn, G. T., 983
Horowitz, M., 527
Horsthemke, B., 1187
Hoyle, L. S., 624
Hu, X., 682
Huang, L.-S., 1141
Huckle, P., 988
Huebner, K., 26
Huether, C. A., 188 (HGES-E), 1221 (HGES-E)
Huh, T.-L., 340
Hutz, M. H., 1112

Ikonen, E., 5
Iles, D., 1082
Iselius, L., 120
Iwanaga, T., 1178

Jackson, C. E., 624
Jacobs, P. A., 754
Jacobsen, G., 1101
James, L. A., 316
Jänne, P. A., 1141
Jensson, O., 293
John, S. W. M., 970
Johnson, K., 1073
Jolley, S., 943
Jones, T. A., 1024
Jost, M., 912

Kaback, M. M., 393 (ASHG)
Kadri, A. S., 1024
Kahn, A., 459
Kajiyama, G., 822
Kaplan, F., 126
Kaplan, G. C., 182 (L)
Kaplan, J.-C., 459
Karila, L., 5
Kasturi, R. V., 587
Kato, H., 1041, 1053
Katz, K. S., 672
Kaufman, M., 1095
Kayden, H., 1141
Kerem, B., 395 (L)
Kerr, B., 635 (L)
Khalifa, M. M., 744
Khoury, M. J., 478
Kidd, J. R., 624, 950
Kidd, K. K., 624, 950
Kimura, A., 1178
King, M.-C., 12
Klinger, K., 983
Knowler, W. C., 613
Kokotsis, G., 126
Koler, R. D., 652
Kolodny, E. H., 329, 527, 817
Korneluk, R. G., 1082
Kourides, I. A., 988
Krantz, D. A., 587
Kroos, M. A., 45
Kruckeberg, W. C., 1001 (L)
Kunkel, L. M., 672
Kwiatkowski, D. J., 559

Labella, T., 95
Laberge, C., 970
La Du, B. N., 934
Laframboise, R., 970
Lafrenie, R. M., 729
Lagerström, M., 120
Laird, C. D., 443, 696
Lamb, J., 925, 1112
Lamb, M. M., 696
Lambert, B., 1095
Langaney, A., 383
Lange, B. J., 26
Lange, K., 789
Larsen, J. W., 587
Lawrence, D. N., 613
Leblond, S., 1082
Ledbetter, D. H., 559, 776, 801
Ledbetter, S., 776
Ledley, F. D., 539
Lee, M., 754
Lehesjoki, A.-E., 53
Lehrach, H., 762
Leichtman, L. G., 1001 (L)
Leonard, C., 518
Leppert, M., 943
Levinson, B., 53
Liao, S., 1095
Liechti-Gallati, S., 1090
Lightstone, H., 934
Lin, K. T., 1001 (L)
Lindenbaum, R. H., 1112, 1127
Litt, M., 776
Little, R. D., 95
Lockridge, O., 934
Lombes, A., 418
Lovrien, E., 652
Lumetta, M., 539
Lupski, J. R., 801
Luty, J. A., 776

Mabuchi, K., 1041
McBride, O. W., 340
McDermid, H., 888
MacDonald, M. E., 762
MacGillivray, M. H., 1127
McGuffin, P., 994
McGuire, M. C., 934
McKendry-Smith, S., 286
MacKenzie, A. E., 1082
MacLennan, D. H., 1082
Maire, I., 329
Maitland, N. J., 1000 (L)
Malcolm, S., 92
Malhotra, U., 789
Maloney, E. K., 478
Mandel, J. L., 133, 459, 720, 906
Marci, J. N., 587
Marinkovic, D., 377
Marion, R. W., 896
Markin, R. S., 1001 (L)
Martini, A., 661
Martuza, R. L., 323
Maruyama, T., 602
Matalon, R., 1001 (L)
Mathew, C., 293
Matsunaga, E., 602
Matsuo, Y., 85
Mattei, J. F., 518
Matteson, K. J., 182 (L)
May, B. K., 107
May, K. K., 754
Meeker, C. A., 369
Menashe, V., 652
Meneses, M. G., 1163
Merriwether, D. A., 613
Meyer, L. J., 912
Mhatre, A., 1095
Mickelson, K. N. P., 138

Middleton-Price, H. R., 92
Migeon, B. R., 744
Miki, T., 1073
Miller, D. A., 784
Miller, O. J., 784
Milsark, I. W., 672
Milunsky, A., 397 (L)
Mischke, D. M., 548
Mitsumoto, H., 817
Mohandas, T. K., 369
Mohrenweiser, H. W., 63
Monteiro, C., 92
Moraes, C. T., 418
Morgan, K., 126, 434, 983
Morgan-Hughes, J. A., 428
Morton, C. C., 559
Morton, N. E., 377
Moser, H., 1090
Mott, M. G., 1000 (L)
Mueller, O. T., 182 (L), 729
Mulinare, J., 478
Mulivor, R., 286
Mullis, P., 1090
Mulvihill, J. J., 377, 1200
Murphy, E. G., 682
Murray, J. C., 486
Myers, J. C., 1024
Myers, S., 624

Nagarajan, L., 26
Nakamura, H., 602
Nakamura, Y., 486, 801, 925
Nakase, H., 418
Nance, W. E., 646 (E)
Narod, S. A., 266
Navon, R., 817
Naylor, E. W., 1001 (L)
Neel, J. V., 63, 1041, 1053
Neilsen, J., 754
Newton, V., 1017
Nicholls, A., 293
Nicholls, R. D., 1112
Nicole, A., 518
Nimmo, E., 1073
Nishimura, D. Y., 486
Nitowsky, H., 1222 (HGES-L)
Nogueira, C. P., 934
Nowell, P. C., 26
Nowinski, G. P., 1101

Oberlé, I., 720
O'Brien, W. E., 1001 (L)
O'Connell, P., 943
Ogden, B., 943
Ogilvie, D., 293
Ohno, K., 329
Okano, Y., 18, 919
Olek, K., 1158
Olson, S., 340, 661
Omenn, G. S., 1006 (BR)
Omoto, K. H., 581
Oostra, B. A., 45
O'Shaughnessy, D. F., 144
Ostrer, H., 182 (L)
Otake, M., 1053
Ott, J., 5, 219 (E)
Owen, F., 1215 (L)
Owen, M. J., 316

Pai, G. S., 350
Pakstis, A. J., 624
Palmieri, G., 720
Palo, J., 5
Palotie, A., 5
Passarge, E., 1187
Patel, P. I., 801
Pauli, R. M., 486
Peltonen, L., 5
Peng, R., 822
Perez, M. P., 1163
Pettersson, U., 120
Petty, R. K. H., 428
Phillips, J. A. III, 182 (L)
Phillips, M., 1082
Piepkorn, M., 912
Pihlajaniemi, T., 1024
Pinsky, L., 1095
Pison, G., 383
Plaetke, R., 943
Plumridge, D., 208 (HGES)
Pohjolainen, E.-R., 1024
Poissonnier, M., 518
Pope, F. M., 293
Porta, G., 95
Poulter, M., 1215 (L)
Poustka, A., 762
Prieur, M., 518
Prior, J. F., 138
Proia, R. L., 817

Radojičić, Č., 377
Radovanović, Z., 377
Rahmani, Z., 518
Rao, D. C., 37, 168
Rasmussen, S. A., 478
Ratcliffe, S., 754
Ray, P. N., 395 (L), 682
Read, A. P., 1017
Reade, T., 434
Redekopp, S., 286
Reeders, S. T., 925, 1112
Reiss, A. L., 744
Reuser, A. J. J., 45
Reynolds, J., 789
Riccardi, V. M., 190 (HGES)
Rice, T., 37
Richards, C. S., 672
Rinaldi, A., 738
Risch, N. J., 222, 229, 242, 533
Rizzuto, R., 418
Robinson, A., 754
Robinson, R. M., 874
Rocchi, M., 738, 784
Roe, C. R., 1001 (L)
Roesel, A. R., 1001 (L)
Rogers, J., 1149
Romano, D., 762
Romano, L., 1004 (L)
Romeo, G., 1004 (L)
Rommens, J., 395 (L)
Ronchetto, P., 1004 (L)
Rosa, N. E., 729
Rosenfield, R. L., 1095
Rouleau, G. A., 323
Rowley, P. T., 851 (BR)
Rozen, R., 970
Ruano, G., 1149
Rundle, S., 1073

Sai, T., 1095
Sanchez, S. G., 1163
Sanchez-Mazas, A., 383, 502
Sandhoff, K., 329
Santoli, D., 26
Sarfarazi, M., 1214 (L)
Sasazuki, T., 1178
Satoh, C., 1053
Schepens, J., 492
Scherer, G., 925
Schinzel, A., 486
Schlessinger, D., 95
Schmid, M., 553
Schneider, N. R., 672
Schneider, V., 1090
Schon, E. A., 418
Schork, M. A., 396 (L)

Schork, N. A., 396 (L)
Schull, W. J., 1041, 1053
Schurr, T. G., 613
Schwartz, C., 182 (L)
Schwartz, R. C., 293, 1214 (L)
Schwartz, R. H., 983
Schwartz, S., 434
Scott, J. A., 1223 (HGES)
Scriver, C. R., 126, 434, 970
Seargeant, L. E., 280
Sedlacek, Z., 762
Seino, S., 1095
Seizinger, B. R., 323
Sevin, A., 383
Shale, H., 533
Shapira, E., 1001 (L)
Shapiro, L. J., 369
Sheer, D., 1024
Sheffield, V. C., 852 (BR)
Shelbourne, P., 1073
Sheu, K.-F. R., 874
Shields, E. D., 434
Shiokawa, S., 602
Shows, T. B., 729
Siciliano, M. J., 492, 1073
Sieber, W. K., 568
Simpson, J. L., 847 (L)
Simpson, N. E., 624
Sinet, P. M., 518
Sing, C. F., 1231 (HGES-BR)
Siniscalco, M., 738
Sit, K. H., 179 (L)
Skolnick, M. H., 912
Slaugenhaupt, S. A., 801
Smeets, H., 492
Smith, K. D., 452
Smouse, P. E., 63
Soda, M., 1041
Solomon, E., 1024
Somer, H., 5
Song, B. J., 340
Sparkes, R. S., 486
Spence, M. A., 486
Stahnke, G., 470
Stanislovitis, P., 983
Stanley, W. S., 350
Starman, B. J., 591, 975, 1034
Steinmann, B., 18, 293
Stephens, J. C., 1149
Stern, H. J., 369
Stewart, R. A., 795
Stine, O. C., 452
Superneau, D. W., 323
Sutherland, G. R., 107
Suzuki, K., 329
Sved, J. A., 443
Sykes, B., 293
Szabo, P., 874

Takata, K., 822
Tanaka, A., 329
Taylor, H. A., 1001 (L)
Tedesco, T. A., 1001 (L)
Thomas, G. H., 817
Thompson, E., 293
Thompson, J. N., 1001 (L)
Thompson, M. W., 682
Thorne, J. L., 696
Tilley, B. C., 1101
Tocci, P. M., 1001 (L)
Tolan, D. R., 1194
Tolmie, J. L., 1112
Toriello, H. V., 190 (HGES)
Trapman, J., 1095
Trent, R. J., 138
Trifiro, M., 1095
Triggs-Raine, B. L., 183 (L)
Tsintsof, A. S., 138
Tsipouras, P., 293, 643 (E), 896, 1214 (L)
Tsuda, K., 602
Tsui, L. C., 395 (L)
Turco, A., 912

Upholt, W. B., 896
Urabe, K., 1178

Valli, M., 661
van Blyenburgh, N. H., 383
van den Berghe, H., 26
van der Ploeg, A. T., 45
Van der Spek, A. F. L., 934
van Duin, M., 492
Van Dyke, D. L., 1101
Varey, P. A., 729
Veech, R. L., 340
Verdy, M., 624
Verma, R. S., 398 (L)
Volanakis, J. E., 956

Wada, M., 95
Waelsch, S. G., 1222 (HGES-L)
Walker, A. P., 1223 (HGES)
Wallace, D. C., 613
Wallis, G. A., 293, 1034
Walters, M., 635 (L)
Wang, T., 18
Wappner, R. S., 843
Ward, J. C., 1001 (L)
Ward, K., 943
Watkins, S. C., 672
Weatherall, D. J., 144, 1112, 1127
Webb, G. C., 308
Weber, C. A., 492
Weidinger, S., 810, 1158
Weil, J., 1219 (BR)
Weiss, K. M., 613
Weiss, L., 1101
Weleber, R. G., 652
Wellesley, D., 1017
Wenstrup, R. J., 975
Wertelecki, W., 323
Wertz, D. C., 1200
Wette, R., 168
Whaley, W. L., 762
White, R., 943
Wieringa, B., 492, 1082
Wild, A. G., 548
Wilkie, A. O. M., 1112, 1127
Will, H., 470
Willard, H. F., 273, 776, 1082
Wille, G., 548
Williams, J. C., 1000 (L)
Williamson, J. A., 254
Williamson, R., 316, 1073, 1163
Willing, M. C., 975
Wilson, G. N., 1101
Wilson, W. G., 1001 (L)
Woo, S. L. C., 18, 919
Wordsworth, P., 293
Worsham, M. J., 1101
Worton, R. G., 682, 1082
Wright, E. C., 912
Wu, J., 624

Xiao, G. H., 925

Yen, P. H., 369
Yokoyama, S., 85
Yoshimoto, Y., 1041, 1053
Youngman, S., 762

Zietlin, H. C., 1127
Zhang, B., 843
Zhu, Z. B., 956
Zimran, A., 902
Zinn, A. B., 1034
Zonana, J., 652
Zone, J. J., 912
Zorzato, F., 1082
Zuliani, G., 963

Subject Index to Volume 46

(ASHG) = American Society of Human Genetics report; (E) = Editorial; (HGES) = Human Genetics Education section; (L) = Letter to the Editor; (O) = Opinion; (R) = Review

Abetalipoproteinemia, exclusion of linkage with apo B gene, 1141
Adoption agencies, survey, 208 (HGES)
Adrenoleukodystrophy, red-green visual pigment gene region, 459
Affected relative pairs
  Genetically complex traits, 229
  Marker polymorphism, 242
Ag-system haplotypes, population study, 502
Alcohol dehydrogenase gene, class III, cloning and sequencing of processed pseudogene, 85
Alcoholism, segregation analysis, 879
Allele(s)
  α1-Antitrypsin, normal V_{munich}, IEF pattern, 810
  Heterogeneous, expression of methylmalonyl CoA mutase, 539
Allele frequency, polymorphic keratins K4 and K5, 548
Allelic associations, complement protein C2 gene RFLPs, 956
Allelic diversity, glycogenosis type II, 45
α Gene abnormalities, β-hexosaminidase, 329
α-Globin gene markers, identifying genetic differences, 138
α-Ketoacid dehydrogenase, branched chain, E1α subunit, 843
Alpha polypeptide gene, pyruvate dehydrogenase, 874
Alpha satellite DNA, chromosome 12 subset, 784
α Thalassemia/mental retardation syndromes, clinical features and molecular anlaysis, 1112, 1127
α1-Antitrypsin
  Allele V_{munich}, normal, protein IEF pattern, 810
  Deficiency gene, molecular analysis, 602
  PI Zaugsburg variant, 1158
α1(I) Gene, parental type I collagen, lethal point mutation, 1034
α5(IV) Collagen, molecular cloning, 1024
Alport syndrome region, α5(IV) collagen, 1024
Alu sequences, length polymorphism in adjacent repeated sequences, 963
Alzheimer disease, physical mapping of locus, 316
Amelogenesis imperfecta, X-linked, mapping by linkage analysis, 120
American Society of Human Genetics
  Cystic fibrosis screening statement, 393 (ASHG)
  Education, 208 (HGES)
  Maternal serum alpha-fetoprotein policy statement update, 847 (L)
Androgen insensitivity, androgen receptor gene point mutation, 1095
Androgen receptor gene, point mutation, 1095
Aneuploidy
  Chromosome Y, sperm nuclei, 553
  Cultured lymphocytes, frequency with age and gender, 1101
Apolipoprotein A-II deficiency, familial, splice-junction mutation, 822
Apolipoprotein B gene, exclusion of linkage with abetalipoproteinemia, 1141
Appendicitis, acute, inheritance, 377
Arylsulfatase-C isoenzymes, genes escaping X inactivation, 729
Asilomar meeting, genetic counseling education, 1223 (HGES)
Ataxia, autosomal dominant, locus heterogeneity, 1163
Ataxia-telangiectasia gene, distinction from ETS-1 gene, 789
Atomic bomb survivors
  Genetic doubling dose of radiation in offspring, 1053
  Malignant tumors in offspring, 1041
Autosomal dominant ataxia, locus heterogeneity, 1163
Autosomal dominant clefting syndrome, linkage to chromosome 1q, 486
Autosomal dominant inheritance, idiopathic torsion dystonia, 533
Autosomal dominant polycystic kidney disease, genetic recombination, 925

Band number variability, DNA fingerprinting, 358
Bar Harbor course, human genetics education, 192 (HGES)
Beckwith-Wiedemann syndrome, genomic imprinting, 1000 (L)
β-Hexosaminidase α gene abnormalities, GM2 gangliosidosis B1 variant, 329
β-Subunit gene, TSH, nonsense mutation in familial hypothyroidism, 988
β-Thalassemia, haplotype and mutation analysis, 126
Biochemical genetics laboratories, proficiency testing, 1001 (L)
Birth defects, history from maternal interview, 478

Blood pressure, commingling and segregation analysis, 37
Books reviewed, author(s)/editor(s):
Auerbach, A. D., 185
Beaudet, A. L., 637, 848
Falconer, D., 1231 (HGES)
Gardner, R. J. M., 400
Glass, B., 1219
Harper, P. S., 1219
Harris, H., 1007
Hirschhorn, K., 1007
Holtzman, N. A., 1006
Lundsteen, C., 1218
Lusis, A. J., 1217
McKie, R., 215 (HGES)
Mulligan, R., 637
Nienhuis, A. W., 851
Obe, G., 185
Piper, J., 1218
Read, A., 852
Schroeder-Kurth, T. M., 185
Scriver, C. R., 848
Sly, W. S., 848
Sparkes, R. S., 1217
Stamatoyannopoulos, G., 851
Sutherland, G. R., 400
Todes, D., 1234 (HGES)
Valle, D., 848
Verma, I. M., 637
Books reviewed, title:
Advances in Human Genetics, vol. 18, 1007
Automation of Cytogenetics, 1218
Chromosome Abnormalities and Genetic Counseling, 400
Darwin without Malthus, 1234 (HGES)
Fanconi Anemia: Clinical, Cytogenetic, and Experimental Aspects, 185
Gene Transfer and Gene Therapy, 637
Genetic Jigsaw: The Story of the New Genetics, The, 215 (HGES)
Genetic Factors in Atherosclerosis: Approaches and Model Systems, 1217
Guide to the Genetics Collections of the American Philosophical Society, A, 1219
Hemoglobin Switching. Part A: *Transcriptional Regulation*. Part B: *Cellular and Molecular Mechanisms*, 851
Introduction to Quantitative Genetics, 3d ed., 1231 (HGES)
Medical Genetics: An Illustrated Outline, 852
Metabolic Basis of Inherited Disease, The, 6th ed., 848
Practical Genetic Counseling, 3d ed., 1219
Proceed with Caution: Predicting Genetic Risks in the Recombinant DNA Era, 1006
Branched chain α-ketoacid dehydrogenase, E1α subunit, 843
Breast cancer
Exclusion of retinoblastoma gene and chromosome 13q as site of primary lesion, 12
Hereditary, linkage analysis, 266

Cancer
Exclusion of retinoblastoma gene and chromosome 13q as site of primary lesion, 12
Hereditary breast, linkage analysis, 266
Colon, stimulated recessive transmission, 179 (L)
Carboxypeptidase A, *Bgl*II RFLP and mapping, 795
Carrier diagnosis, hyperphosphatemia, 280
Carrier screening, hyperphosphatemia, 280
Charcot-Marie-Tooth disease, autosomal dominant, genetic mapping, 801
Cholinesterase, serum, silent phenotype from frameshift mutation, 934
Chromatid, G2, radiosensitivity in dyskeratosis congenita fibroblasts, 350
Chromosome, yeast artificial
Mapping Xq28 polymorphic loci, 720
Telomere clone, 762
Chromosome 1p36, linkage with cutaneous melanoma–dysplastic nevus syndrome, 912
Chromosome 1p36.1-34, infantile hypophosphatasia, 286
Chromosome 1q, autosomal dominant clefting syndrome, 486
Chromosome 2q37, Waardenburg syndrome type I, 1017
Chromosome 3, enzyme genes of PDH complex, 340
Chromosome 4, RFLP haplotypes, linkage disequilibrium in Huntington disease, 5
Chromosome 5q, gene order and interstitial deletions, 26
Chromosome 7, enzymes of PDH complex, 340
Chromosome 7q31-qter, carboxypeptidase A, 795
Chromosome 9q13-q21, Friedreich ataxia, 133
Chromosome 10, centromere, MEN2A, 624
Chromosome 11, ataxia-telangiectasia gene, 789
Chromosome 12, alpha satellite DNA subset, 784
Chromosome 13q, exclusion as site of primary lesion in breast cancer, 12
Chromosome 16, autosomal dominant polycystic kidney disease, 925
Chromosome 16p13.3, deletions causing α thalasse-

mia/mental retardation syndromes, 1112
Chromosome 17
Linked markers, genetic mapping of Charcot-Marie-Tooth disease, 801
Pericentromeric region, hereditary motor and sensory neuropathy type I, 92
Chromosome 17p11.1-17p12, *UbB* polyubiquitin gene, 308
Chromosome 17p13.3, functional profilin gene, 559
Chromosome 19, myotonic dystrophy locus, 1073
Chromosome 19q13, restriction map, 492
Chromosome 19q13.1, ryanodine receptor gene, 1082
Chromosome 21
Alzheimer disease locus, 316
DNA sequences and chromosome rearrangements, 518
Chromosome 22, neurofibromatosis type 2 gene, 323
Chromosome X
α5(IV) Collagen, 1024
Enzymes of PDH complex, 340
Erythroid 5-aminolevulinate synthase, 107
Parental origin in 47,XXX, 754
Polymorphic microsatellite VNTRs, 776
Proximal short arm, X inactivation, 273
Chromosome Xq24-Xq28, mapping by yeast artificial chromosomes, 95
Chromosome Xq28, polymorphic loci, 720
Chromosome Y, aneuploidy in sperm nuclei, 553
Chromosome rearrangements, mapping by slot blot method, 518
CKMM gene, physical linkage to ERCC1 and ERCC2 genes, 492
Clefting syndrome, autosomal dominant, linkage to chromosome 1q, 486
Clone(s)/cloning
Mapping Xq28 polymorphic loci, 720
Molecular, α5(IV) collagen, 1024
Processed pseudogene from class III ADH gene, 85
Telomere, yeast artificial chromosome, 762
Codon 129 changes, prion protein gene, 1215
COL1A1 and COL1A2, linkage to dominantly inherited osteogenesis imperfecta, 293
COL2A1 gene
Genetic linkage to spondyloepiphyseal dysplasia congenita, 896
Restriction-site linkage disequilibrium, 1214
Collagen
α1(I) Gene lethal point mutation, 1034
α5(IV), molecular cloning, 1024
Type I loci, linkage to dominantly inherited osteogenesis imperfecta, 293
Collagen gene, type 1, parental mosaicism for mutation, 591
Colon cancer, simulated recessive transmission, 179 (L)
Commingling analysis, blood pressure, 37
Complement protein C2, RFLPs' allelic associations, 956
Cosegregation, elastin-associated microfibrillar abnormalities and Marfan phenotype, 652
Cosmid clone, mapping Xq28 polymorphic loci, 720
Cutaneous melanoma–dysplastic nevus syndrome, linkage with 1p36, 912
Cystic fibrosis
Mutation(s), 983
Nonradioactive detection, 395 (L)
Recombination, 1004 (L)
Screening, ASHG statement, 393 (ASHG)

D4S43 locus, exclusion of tight linkage with Huntington disease, 5
D9S15, linkage disequilibrium with Friedreich ataxia, 133
Deletion(s)
Functional profilin gene in Miller-Dieker syndrome, 559
Interstitial, and gene order, chromosome 5q, 18
16p13.3, α thalassemia/mental retardation syndromes, 1112
Δ508, recombination in cystic fibrosis family, 1004 (L)
Diagnosis
Carrier, hyperphosphatemia, 280
Neurofibromatosis, 1, 943
Prenatal, infantile hypophosphatasia, 286
Diagnostic heteroduplexes, Tay-Sachs disease, 183 (L)
Diagnostic laboratories, DNA, 182 (L)
DiGeorge syndrome, molecular studies, 888
Disease, genomic imprinting, 857 (R)
Disequilibrium, linkage
COL2A1 gene restriction sites, 1214
XY274 polymorphism and pseudoautosomal DNA diagnostic laboratories, 182 (L)
DNA
Alpha satellite, chromosome 12 subset, 784
Mitochondrial, heteroplasmy, 428
Mutations, 613
Nucleotide sequence differences in noncoding region, 828
Sickness and health, 415 (E)
Sequence quantification by slot blot method, 518
DNA analysis, individual identification, 631 (ASHG)
DNA fingerprinting, forensic identification, 358
DNA markers
Neurofibromatosis 1 diagnosis, 943
Prenatal diagnosis of infantile hypophosphatasia, 286

Duchenne muscular dystrophy
Locus, duplicational mutation, 682
RFLPs for cDNA clones, 1090
Dyskeratosis congenita fibroblasts, G2 chromatid radiosensitivity, 350
Dysmorphic syndromes, mapping, 1013 (E)

E1α subunit, branched chain α-ketoacid dehydrogenase, 843
Education
ASHG, 208 (HGES)
Asilomar meeting on genetic counseling, 1223 (HGES)
Human genetics, 188 (HGES), 190 (HGES)
Bar Harbor course, 192 (HGES)
Teaching in medical schools, 1222 (HGES-L)
Environmental index, genetic epidemiology, 168
Enzymes, PDH complex, gene mapping, 340
Epidemiology, genetic, environmental index, 168
ERCC1 and ERCC2 genes, physical linkage to CKMM gene, 492
Ethical dilemmas, cross-cultural, 1200
ETS-1 gene, distinction from ataxia-telangiectasia gene, 789
Exon-Alu interchange, partial gene duplication in LPL deficiency, 112

Familial aggregation, inheritance of acute appendicitis, 377
Fibroblasts, dyskeratosis congenita, G2 chromatid radiosensitivity, 350
Forensic identification, DNA fingerprinting, 358
Founder-effect population, autosomal dominant ataxia locus heterogeneity, 1163
Fragile site, fragile-X syndrome, methylation of flanking genes, 744
Fragile-X mutation, heterozygotes, mental retardation, 738
Fragile-X syndrome
Methylation of genes flanking fragile site, 744
Population genetics, 443
X-inactivation imprinting model, 696
Frameshift mutation, serum cholinesterase silent phenotype, 934
Friedreich ataxia, mapping to chromosome 9q13-q21 and linkage disequilibrium with D9S15, 133
Fructose intolerance, hereditary, heterozygosity, 1194

G2 chromatid radiosensitivity, dyskeratosis congenita fibroblasts, 350
Gangliosidosis, GM2
Ashkenasi Jewish and non-Jewish patients, 817
B1 variant, 329
Gaucher disease
Genotype assignment, 527
Mutation, linkage with *Pvu*II polymorphism, 902
Gene conversion
PAH locus, 970
Steroid 21-hydroxylase, 1178
Gene duplication, exon-Alu interchange, LPL deficiency, 112
Genetic counseling, Asilomar meeting on education, 1223 (HGES)
Genetic differentiation, interethnic, GM polymorphism, 383
Genetic doubling dose, radiation in offspring of A-bomb survivors, 1053
Genetic epidemiology, environmental index, 168
Genetic heterogeneity, Wiskott-Aldrich syndrome, 906
Genetic linkage, spondyloepiphyseal dysplasia congenita and COL2A1, 896
Genetic loci ordering instability, 1156
Genetic polymorphism, LDL, 502
Genetic recombination, autosomal dominant polycystic kidney disease, 925
Genomic imprinting
Beckwith-Wiedemann syndrome, 1000 (L)
Relevance to disease, 857 (R)
Genotype assignment, Gaucher disease, 527
Germ-line mosaicism, Wiskott-Aldrich syndrome genetic heterogeneity, 906
Globin complex, absence of abnormality in α thalassemia/mental retardation syndromes, 1127
Globin genes, population origins/affinities, 144
Glucocerebrosidase gene, selective implification, 527
Glycogenosis type II, allelic diversity, 45
GM polymorphism, interethnic genetic differentiation, 383
GM2 gangliosidosis
Ashkenasi Jewish and non-Jewish patients, 817
B1 variant, 329

Haplotype(s)
Ag-system, population study, 502
Chromosome 4 RFLP, linkage disequilibrium in Huntington disease, 5
RFLP 1 and 4 of PAH, 18
Haplotype analysis, β-thalassemia, 126
Haplotype resolution, single-molecule-dilution method, 1149
Hemophilia A, molecular analysis of mutations, 53
Hepatic lipase, abnormalities, 470
Hereditary motor and sensory neuropathy type I, linkage to chromosome 17 pericentromeric region, 92

Heredity, adoption agencies survey, 208 (HGES)
Heteroduplexes, diagnostic, Tay-Sachs disease, 183 (L)
Heterogeneity
  Genetic, Wiskott-Aldrich syndrome, 906
  Locus, autosomal dominant ataxia, 1163
  Subpopulation, DNA fingerprinting, 358
Heteroplasmy, mitochondrial DNA, 428
Heterozygote(s)/heterozygosity
  Fragile-X mutation, mental retardation, 738
  Hereditary fructose intolerance, 1194
Hirschsprung disease, genetic study, 568
Histograms, 396 (L)
Homology, Waardenburg syndrome type I and Splotch mouse, 1017
Homology map, human/mouse, mapping dysmorphic syndromes, 1013 (E)
Human Genetics Education section, 1221 (HGES-E)
Huntington disease
  Linkage disequilibrium of chromosome 4 RFLP haplotypes and exclusion of linkage with D4S43 locus, 5
  Predictive testing in childhood, 1 (O)
  Selection coefficients, 452
  Yeast artificial chromosome telomere clone, 762
Hybridization, in situ nonradioactive, chromosome Y aneuploidy, 533
Hyperphosphatemia, infantile hypophosphatasia, 280
Hypophosphatasia, infantile
  Hyperphosphatemia, 280
  Localization and prenatal diagnosis, 286
Hypophosphatemia, X-linked, expression of mutant gene, 434
Hypothyroidism, familial, nonsense mutation in TSH β-subunit gene, 988

Identity-by-state methods, linkage analysis, 254
Idiopathic torsion dystonia, segregation analysis, 533
Imprinting, genomic
  Beckwith-Wiedemann syndrome, 1000 (L)
  Relevance to disease, 857 (R)
Imprinting hypothesis, fragile-X syndrome, 744
Imprinting model, X-inactivation, fragile-X syndrome, 696
Inactivation
  Skewed X, Duchenne muscular dystrophy in female MZ twin, 672
  X, arylsulfatase-C isoenzymes, 729
Individual variation, 649 (O)
Infantile hypophosphatasia
  Hyperphosphatemia, 280
  Localization and prenatal diagnosis, 286
Informative meioses, pedigree selection for linkage analysis of quantitative trait, 581
Inheritance
  Acute appendicitis, 377
  Autosomal dominant, idiopathic torsion dystonia, 533
Insertion mutation, Tay-Sachs disease, 183 (L)
Interstitial deletions, and gene order, chromosome 5q, 26
Isoelectric focusing pattern, protein, normal α1-antitrypsin allele V_{munich}, 810
Isoenzymes, arylsulfatase-C, genes escaping X inactivation, 729

Kearns-Sayre syndrome, transcription and translation of deleted mitochondrial genomes, 418
Keratins, K4 and K5, polymorphic, allele frequencies and segregation, 548

Length polymorphisms, repeated sequences adjacent to Alu sequences, 963
Linkage
  Autosomal dominant clefting syndrome and chromosome 1q, 486
  Cutaneous melanoma–dysplastic nevus syndrome and 1p36, 912
  Dominantly inherited osteogenesis imperfecta and type I collagen loci, 293
  Genetic, spondyloepiphyseal dysplasia congenita and COL2A1, 896
  Hereditary motor and sensory neuropathy type I to chromosome 17 pericentromeric region, 92
  Physical, CKMM and ERCC1 and ERCC2 genes, 492
  *Pvu*II polymorphism and Gaucher disease mutation, 902
Linkage analysis
  Complex human traits, 219 (E)
  Hereditary breast cancer, 266
  Identity-by-state methods, 254
  Lymphoblastoid cell lines, 635 (ASHG)
  Pedigree selection for quantitative trait, 581
  X-linked amelogenesis imperfecta, 120
Linkage disequilibrium
  COL2A1 gene restriction sites, 1214
  Friedreich ataxia and D9S15, 133
  Huntington disease, chromosome 4 RFLP, 5
  XY274 polymorphism and pseudoautosomal boundary, 950
Linkage exclusion, apo B gene and abetalipoproteinemia, 1141
Linkage group, chromosome 19, ryanodine receptor gene placement, 1082
Linkage strategies, genetically complex traits

Affected relative pairs, 229
Marker polymorphism, 242
Multilocus models, 222
Lipase, hepatic, abnormalities, 470
Lipoid proteinosis, selection coefficients, 452
Lipoprotein, low-density, genetic polymorphism, 502
Lipoprotein lipase abnormalities, 470
Lipoprotein lipase deficiency, exon-Alu interchange, partial gene duplication, 112
Locus heterogeneity, autosomal dominant ataxia, 1163
Low-density lipoprotein, genetic polymorphism, 502
Lymphoblastoid cell lines, linkage analysis, 635 (ASHG)
Lyonization, twins/twinning, 646 (E)

Map(s)/mapping
Carboxypeptidase A, 795
Chromosome rearrangements, slot blot method, 518
Dysmorphic syndromes, 1013 (E)
Friedreich ataxia, 133
Genetic, Charcot-Marie-Tooth disease, 801
Human/mouse homology, mapping dysmorphic syndromes, 1013 (E)
Physical, Alzheimer disease locus, 316
And genetic, Xq28 polymorphic loci, 720
X-linked amelogenesis imperfecta, 120
Xq24-Xq28, by yeast artificial chromosomes, 95
Maple syrup urine disease, thiamine responsive, 843
Marfan phenotype, cosegregation with elastin-associated microfibrillar abnormalities, 652
Marfan syndrome, 643 (E)
Asymmetric, unilateral microfibrillar abnormalities, 661
Marker(s)
α-Globin gene, 138
DNA, neurofibromatosis 1 diagnosis, 943
Flanking, neurofibromatosis type 2 gene, 323
Linked
Chromosome 17, genetic mapping of Charcot-Marie-Tooth disease, 801
DNA, prenatal diagnosis of infantile hypophosphatasia, 286
Marker polymorphism, analysis of affected relative pairs, 242
Maternal serum alpha-fetoprotein
ASHG policy statement update, 847 (L)
Patient-specific risk reporting, 587
Medical school attendance, 994
Mental retardation, fragile-X mutation heterozygotes, 738
Mental retardation/α thalassemia syndromes, clinical features and molecular analysis, 1112, 1127
Methylation, genes flanking fragile site in fragile-X syndrome, 744
Methylmalonyl CoA mutase, *mut* methylmalonic acidemia, 539
Microevolution, 63
Microfibrillar abnormalities
Elastin-associated, cosegregation with Marfan syndrome, 661
Unilateral, asymmetric Marfan, 661
Microsatellite VNTRs, polymorphic, X chromosome, 776
Miller-Dieker syndrome, deletion of functional profilin gene, 559
Missense mutations, and RFLP haplotypes 1 and 4 of PAH, 18
Mitochondrial disease, mitochondrial DNA heteroplasmy, 428
Mitochondrial DNA
Heteroplasmy, mitochondrial disease, 428
Mutations, 613
Nucleotide sequence differences in noncoding region, 828
Sickness and health, 415 (E)
Mitochondrial genomes, deleted, transcription and translation in Kearns-Sayre syndromes, 418
Mnichinan, α1-antitrypsin deficiency variant, molecular analysis, 602
Molecular analysis
α Thalassemia/mental retardation syndromes, 1112, 1127
α1-Antitrypsin deficiency gene, 602
Hemophilia A mutations, 53
Molecular cloning, α5(IV) collagen, 1024
Mosaicism
45,X/46,XY, phenotype, 156
Germ-line, Wiskott-Aldrich syndrome genetic heterogeneity, 906
Parental, mutation in COL1A1, lethal osteogenesis imperfecta, 591
Somatic
Bilateral retinoblastoma, 1187
Lethal point mutation in parental COL1A1, 1034
Multilocus models, genetically complex traits, 222
Multiple endocrine neoplasia type 2A, mapping to chromosome 10 centromere, 624
Muscular dystrophy, Duchenne, RFLPs for cDNA clones, 1090
mut methylmalonic acidemia, methylmalonic CoA mutase, 539
Mutation(s)
Cystic fibrosis, 983

Nonradioactive detection, 395 (L)
COL1A1, parental mosaicism, 591
Duplicational, Duchenne muscular dystrophy locus, 682
Fragile-X, heterozygotes, mental retardation, 738
Frameshift, serum cholinesterase silent phenotype, 934
Gaucher disease, linkage with *Pvu*II polymorphism, 902
Hemophilia A, molecular analysis, 53
Insertion, Tay-Sachs disease, 183 (L)
Lethal point, parental COL1A1, 1034
Missense, and RFLP haplotypes 1 and 4 of PAH, 18
Mitochondrial DNA, 613
Nonsense, TSH β-subunit gene, 988
Point, androgen receptor gene, 1095
Recurrent, PAH
Gene, 919
Locus, 970
Splice-junction, familial apo A-II deficiency, 822
Mutation analysis, β-thalassemia, 126
Myotonic dystrophy
Exclusion of ryanodine receptor gene, 1082
Locus, chromosome 19, 1073
MZ twin(s), female, skewed X inactivation and Duchenne muscular dystrophy, 672

Neurofibromatosis
Type 1, diagnosis with DNA markers, 943
Type 2 gene, flanking markers on chromosome 22, 323
Neuropathy, hereditary motor and sensory type I, linkage to chromsome 17pericentromeric region, 92
Noncoding region, mitochondrial DNA, nucleotide sequence differences, 828

Oogonia, progenitor cells, 696
Osteogenesis imperfecta
Lethal, parental mosaicism for mutation in COL1A1, 591
Linkage to type I collagen loci, 293
Nonlethal, prediction of clinical severity, 975
Somatic mosaicism for lethal point mutation in parental COL1A1, 1034

Parental mosaicism, mutation in COL1A1, lethal osteogenesis imperfecta, 591
Pathogenesis, Kearns-Sayre syndrome, 418
Pedigree(s)
Inference of oogonia progenitor cells, 696
Linkage analysis of quantitative trait, 581
Phenotype(s)
Biochemical, prediction of nonlethal osteogenesis imperfecta clinical severity, 975
45,X/46,XY mosaicism, 156
Silent, serum cholinesterase, 934
Phenotype/genotype correlation, Duchenne muscular dystrophy duplicational mutation, 682
Phenylalanine hydroxylase
Gene
Recurrent mutation, 919
RFLP haplotypes 1 and 4, 18
Locus, recurrent mutation, gene conversion, recombination, 925
PI Zaugsburg variant, α1-antitrypsin, 1158
Point mutation
Androgen receptor gene, 1095
Lethal, parental COL1A1, 1034
Policy statement, ASHG, maternal serum alpha-fetoprotein, 847 (L)
Polycystic kidney disease, autosomal dominant, genetic recombination, 925
Polygenic transmission, inheritance of acute appendicitis, 377
Polymorphic keratins K4 and K5, allele frequencies and segregation 548
Polymorphic loci, Xq28, physical and genetic mapping, 720
Polymorphic probe, chromosome 19 myotonic dystrophy locus, 1073
Polymorphism(s)
Genetic, LDL, 502
GM, interethnic genetic differentiation, 383
Length, repeated sequences adjacent to Alu sequences, 963
Marker, analysis of affected relative pairs, 242
*Pvu*II, linkage with Gaucher disease mutation, 902
Restriction-fragment-length
*Bgl*II, carboxypeptidase A, 795
Chromosome 4, linkage disequilibrium in Huntington disease, 5
Complement protein C2 gene, 956
Duchenne muscular dystrophy cDNA clones, 1090
Haplotypes 1 and 4 of PAH, 18
XY274, linkage disequilibrium with pseudoautosomal boundary, 950
Polyposis coli, simulated recessive transmission, 179 (L)
Polyubiquitin gene, *UbB*, localization, 308
Population genetics, fragile-X syndrome, 443
Population screening, cystic fibrosis, 394 (L)

Porphyria variegata, selection coefficients, 452
Predictive testing, Huntington disease in childhood, 1 (O)
Prenatal diagnosis
  45,X/46,XY mosaicism phenotype, 16
  Infantile hypophosphatasia, 286
Prion protein gene, codon 129 changes, 1215
Processed pseudogene, from class III ADH gene, 85
Proficiency testing, biochemical genetics laboratories, 1001 (L)
Profilin gene, functional, localization to 17p13.3 and deletion in Miller-Dieker syndrome, 559
Progenitor cells, oogonia, 696
Protein, prion gene codon 129 changes, 1215
Protein IEF pattern, normal α1-antitrypsin allele V_{munich}, 810
Proteinosis, lipoid, selection coefficients, 452
Pseudoautosomal boundary, linkage disequilibrium with *XY274* polymorphism, 950
Pseudogene, processed, from class III ADH gene, 85
*Pvu*II polymorphism, linkage with Gaucher disease mutation, 902
Pyruvate dehydrogenase, alpha polypeptide gene X linkage, 874
Pyruvate dehydrogenase complex, enzyme gene mapping, 340

Quantitative trait, pedigree selection for linkage analysis, 581

Radiation, genetic doubling dose in offspring of A-bomb survivors, 1053
Radiosensitivity, G2 chromatid, 350
Recessive transmission, simulated, polyposis coli and colon cancer, 179 (L)
Recombination
  Cystic fibrosis family, 1004 (L)
  Genetic, autosomal dominant polycystic kidney disease, 925
  PAH locus, 970
Recurrent mutation, PAH
  Gene, 919
  Locus, 970
Red-green visual pigment gene region, adrenoleukodystrophy, 459
Restriction map, chromosome 19q13, 492
Restriction-fragment-length polymorphism(s)
  *Bgl*II, carboxypeptidase A, 795
  Chromosome 4, linkage, disequilibrium in Huntington disease, 5
  Complement protein C2 gene, 956
  Duchenne muscular dystrophy cDNA clones, 1090
  Haplotypes 1 and 4 of PAH, 18
Retinoblastoma, bilateral, somatic mosaicism, 1187
Retinoblastoma gene, exclusion as site of primary lesion in breast cancer, 12
"Reverse genetic" medicine, 407 (O)
Risk reporting, patient-specific, maternal serum alpha-fetoprotein, 587
Ryanodine receptor gene, mapping, placement, exclusion, 1082

Screening
  Carrier, hyperphosphatemia, 280
  Cystic fibrosis, ASHG statemet, 393 (ASHG)
  Population, cystic fibrosis, 394 (L)
Segregation, polymorphic keratins K4 and K5, 548
Segregation analysis
  Alcoholism, 879
  Blood pressure, 37
  Idiopathic torsion dystonia, 533
Selection coefficients, Huntington disease, porphyria variegata, lipoid proteinosis, 452
Selective amplification, glucocerebrosidase gene, 527
Sequencing, processed pseudogene from class III ADH gene, 85
Silent phenotype, serum cholinesterase, 934
Single-molecule-dilution method, haplotype resolution, 1149
Slot blot method, quantification of DNA sequences and mapping of chromosome rearrangements, 518
Somatic mosaicism
  Bilateral retinoblastoma, 1187
  Lethal point mutation in parental COL1A1, 1034
Sperm nuclei, chromosome Y aneuploidy, 553
Splice-junction mutation, familial apolipoprotein A-II deficiency, 822
Splotch mouse, homology to Waardenburg syndrome type I, 1017
Spondyloepiphyseal dysplasia congenita, genetic linkage to COL2A1, 896
Steroid sulfatase gene, XX males, 369
Steroid 21-hydroxylase, gene conversion, 1178

Taxonomy, consensus based on genetic and linguistic affinity, 63
Tay-Sachs disease, insertion mutation, 183 (L)
Telomere clone, yeast artificial chromosome, 762
Thalassemia, α/mental retardation syndromes, clinical features and molecular analysis, 1112, 1127
Thyroid-stimulating hormone β-subunit gene, nonsense mutation in familial hypothyroidism, 988

Torsion dystonia, idiopathic, segregation analysis, 533
Transcription, deleted mitochondrial genomes in Kearns-Sayre syndrome, 418
Translation, delected mitochondrial genomes in Kearns-Sayre syndrome, 418
Tumors, malignant, offspring of A-bomb survivors, 1041
Twin(s)/twinning
  Female MZ, skewed X inactivation and Duchenne muscular dystrophy, 672
  Lyonization, 646 (E)

UbB polyubiquitin gene, localization, 308

Van der Woude syndrome, autosomal dominant, linkage to chromosome 1q, 486
Variable number of tandem repeats, polymorphic microsatellite, X chromosome, 776
Visual pigment gene region, red-green, adrenoleukodystrophy, 459

Waardenburg syndrome type I, assignment to 2q37 and homology to Splotch mouse, 1017
Wiskott-Aldrich syndrome, genetic heterogeneity, 906

X inactivation, 273
  Arylsulfatase-C isoenzymes, 729
  Imprinting model
    Fragile-X syndrome, 696
    Population genetics of fragile X, 443
  Mental retardation in fragile-X heterozygotes, 738
X linkage, pyruvate dehydrogenase alpha polypeptide gene, 874
X-linked amelogenesis imperfecta, mapping by linkage analysis, 120
X-linked hypophosphatemia, expression of mutant gene, 434
XX males, steroid sulfatase gene, 369
XY274 polymorphism, linkage disequilibrium with pseudoautosomal boundary, 950

Yeast artificial chromosome
  Mapping Xq28 polymorphic loci, 720
  Telomere clone, 762